Intercept Pharmaceuticals To Provide 2013 Update On Clinical Programs For Obeticholic Acid On January 9
1/3/2014 9:46:23 AM
NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will provide an update on the progress of its clinical development programs after the NASDAQ Market closes on January 9, 2014. This update will provide, among other items, information on the completion of the double-blind phase of the POISE trial, top line data from the OBADIAH and PESTO trials and 2014 anticipated milestones. Intercept management will conduct a conference call and audio webcast at 4:30 p.m. EDT on the same day.
Help employers find you! Check out all the jobs and post your resume.
comments powered by